PENN AVENUE PARTNERS

Lobbying for ALKERMES, INC. · Pharmaceutical manufacturing and biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Oct 3, 2025

Lobbying activity 1

Pharmacy

Regulatory and legislative issues impacting Alkermes. Appropriations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.